The HER2-low and -ultralow breast tumor classifications were previously considered to be HER2 negative. HER2 classification relies on immunohistochemistry (IHC) and fluorescence in situ ...

HER2-ultralow is characterized by an IHC score of 0 with more than 0% but no more than 10% staining in tumor cells. A total of 105 pathologists from 10 countries in Asia and South America with ...

An IHC score of 3+ is HER2-positive breast cancer. If breast cancer comes back or spreads, your HER2 status should be retested because it can change. [8] Prognosis for HER2-Positive Breast Cancer.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The two main types of tests used to detect breast cancer HER2 status are: Immunohistochemistry assay (IHC). This test uses a chemical dye to stain the HER2 proteins.

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than ...

Lunit’s SCOPE HER2 AI model demonstrated an 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry (IHC).

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...

Enhertu ® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or ...

JSKN003-101 (NCT05494918) is an open-label, multicenter, dose-escalation Phase I clinical study conducted in Australia, enrolling patients with advanced solid tumors expressing HER2 (IHC≥1+) or ...

An IHC score of 1+ or 2+ along with a negative FISH test result is considered HER2-low breast cancer. An IHC score of 3+ is considered HER2-positive breast cancer.

HER2 classification relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which examines the number of copies of the HER2 gene inside a cancer cell.